| DAA2080 |
ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) decreases with age |
Molecular |
ovary |
Human |
UBE2D2 |
48.2% Decrease Gene Expression Level |
|
| DAA491 |
ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast) |
Molecular |
skeletal muscle |
Human |
UBE2E2 |
5.0% Increase Gene Expression Level |
|
| DAA1889 |
ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans) |
Molecular |
skeletal muscle |
Mouse |
Ube2g1 |
2.0% Decrease Gene Expression Level |
|
| DAA1836 |
ubiquitin-conjugating enzyme E2L 3 |
Molecular |
muscle |
Mouse |
Ube2l3 |
2.0% Decrease Gene Expression Level |
|
| DAA1274 |
ubiquitin specific peptidase 37 |
Molecular |
brain |
Mouse |
Usp37 |
7.0% Increase Gene Expression Level |
|
| DAA2115 |
ubiquitin specific peptidase 42 increases with age |
Molecular |
ovary |
Human |
USP42 |
60.0% Increase Gene Expression Level |
|
| DAA375 |
ubiquitin specific peptidase 6 (Tre-2 oncogene) |
Molecular |
skeletal muscle |
Human |
USP6 |
5.0% Increase Gene Expression Level |
|
| DAA1108 |
UDP-Gal:betaGal Beta 1,3-galactosyltransferase Polypeptide 6 |
Molecular |
temporal lobe |
Human |
B3GALT6 |
Increase DNA Methylation |
|
| DAA1105 |
UDP-Gal:betaGal Beta 1,3-galactosyltransferase Polypeptide 6 |
Molecular |
cerebellum |
Human |
B3GALT6 |
Increase DNA Methylation |
|
| DAA1107 |
UDP-Gal:betaGal Beta 1,3-galactosyltransferase Polypeptide 6 |
Molecular |
pons |
Human |
B3GALT6 |
Increase DNA Methylation |
|
| DAA1106 |
UDP-Gal:betaGal Beta 1,3-galactosyltransferase Polypeptide 6 |
Molecular |
frontal lobe |
Human |
B3GALT6 |
Increase DNA Methylation |
|
| DAA1324 |
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 |
Molecular |
hematological system |
Mouse |
B3galt1 |
36.0% Increase Gene Expression Level |
|
| DAA2106 |
uridine-cytidine kinase 1-like 1 increases with age |
Molecular |
ovary |
Human |
UCKL1 |
86.0% Increase Gene Expression Level |
|
| DAA900 |
Urine concentrating capacity decreases |
Physiological |
renal tubule |
Human |
— |
— |
|
| DAA966 |
Vaccination antibody response is impaired |
Physiological |
immune system |
Human |
— |
— |
|
| DAA384 |
vacuolar protein sorting 13 homolog C (S. cerevisiae) |
Molecular |
skeletal muscle |
Human |
VPS13C |
3.0% Increase Gene Expression Level |
|
| DAA2104 |
vacuolar protein sorting 13 homolog C (S. cerevisiae) decreases with age |
Molecular |
ovary |
Human |
VPS13C |
58.7% Decrease Gene Expression Level |
|
| DAA1061 |
Variability in clearance of hepatically metabolized drugs |
Physiological |
liver |
Human |
— |
— |
|
| DAA778 |
Variability of performance for multiple cognitive tasks increases |
Psychological |
brain |
Human |
— |
— |
|
| DAA2043 |
Variations in body weight |
Physiological |
whole body |
Human |
— |
— |
|
| DAA2044 |
Variations in fat mass |
Physiological |
adipose tissue |
Human |
— |
— |
|
| DAA423 |
vascular endothelial growth factor B |
Molecular |
skeletal muscle |
Human |
VEGFB |
6.0% Decrease Gene Expression Level |
|
| DAA896 |
Vasodilation induced by acetylcholine or sodium reduced |
Physiological |
renal vasculature |
Human |
— |
— |
|
| DAA1372 |
vasorin |
Molecular |
hematological system |
Mouse |
Vasn |
10.0% Decrease Gene Expression Level |
|
| DAA1888 |
VDNA-damage regulated autophagy modulator 2 |
Molecular |
skeletal muscle |
Mouse |
Dram2 |
16.0% Increase Gene Expression Level |
|